Production (Stage)
Collegium Pharmaceutical, Inc.
COLL
$29.18
-$0.42-1.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 177.76M | 181.95M | 159.30M | 145.28M | 144.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 177.76M | 181.95M | 159.30M | 145.28M | 144.92M |
| Cost of Revenue | 21.48M | 24.22M | 20.41M | 19.96M | 18.95M |
| Gross Profit | 156.27M | 157.73M | 138.90M | 125.32M | 125.97M |
| SG&A Expenses | 76.42M | 58.65M | 42.07M | 43.34M | 41.98M |
| Depreciation & Amortization | 55.47M | 55.47M | 40.80M | 34.52M | 34.52M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 153.38M | 138.34M | 103.28M | 97.81M | 95.45M |
| Operating Income | 24.38M | 43.61M | 56.03M | 47.47M | 49.47M |
| Income Before Tax | 3.12M | 17.27M | 15.58M | 29.10M | 36.62M |
| Income Tax Expenses | 705.00K | 4.73M | 6.25M | 9.49M | 8.91M |
| Earnings from Continuing Operations | 2.42M | 12.54M | 9.34M | 19.61M | 27.71M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.42M | 12.54M | 9.34M | 19.61M | 27.71M |
| EBIT | 24.38M | 43.61M | 56.03M | 47.47M | 49.47M |
| EBITDA | 80.94M | 100.12M | 97.77M | 82.94M | 84.91M |
| EPS Basic | 0.08 | 0.39 | 0.29 | 0.60 | 0.86 |
| Normalized Basic EPS | 0.11 | 0.44 | 0.79 | 0.70 | 0.71 |
| EPS Diluted | 0.07 | 0.35 | 0.27 | 0.52 | 0.71 |
| Normalized Diluted EPS | 0.11 | 0.35 | 0.64 | 0.56 | 0.55 |
| Average Basic Shares Outstanding | 31.79M | 32.08M | 32.26M | 32.43M | 32.33M |
| Average Diluted Shares Outstanding | 32.84M | 40.11M | 40.16M | 40.38M | 41.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |